Table 4.
Outcomes in the General Cohort
| Low/Intermediate risk | High risk | Very high risk | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CS, N=951 | CS+TCZ, N=54 | p value | CS, N=4381 | CS+TCZ, N=554 | p value | CS, N=1542 | CS+TCZ, N=238 | p value | |
| In-hospital death | 85 (8.9) | 4 (7.4) | 1.000 | 1201 (27.4) | 13 (20) | <0.001 | 630 (40.9) | 57 (23.9) | <0.001 |
| HFNC | 59 (6.2) | 16 (29.6) | <0.001 | 452 (10.4) | 156 (28.3) | <0.001 | 192 (12.5) | 74 (31.2) | <0.001 |
| NIMV | 32 (3.4) | 10 (18.5) | <0.001 | 266 (6.1) | 103 (18.6) | <0.001 | 130 (8.4) | 39 (16.4) | <0.001 |
| IMV | 30 (3.2) | 9 (16.7) | <0.001 | 268 (6.1) | 123 (22.2) | <0.001 | 149 (9.7) | 68 (28.6) | <0.001 |
| ICU | 47 (4.9) | 11 (20.4) | <0.001 | 375 (8.6) | 168 (30.3) | <0.001 | 188 (12.2) | 84 (35.3) | <0.001 |
| Length of stay (days), median [IQR] | 8 [5–12] | 12 [8–18.5] | <0.001 | 9 [6–13] | 14 [10–20] | <0.001 | 9 [5–14] | 15 [10–23] | <0.001 |
HFNC high-flow nasal cannula, NIMV non-invasive mechanical ventilation, IMV invasive mechanical ventilation, ICU intensive care unit, IQR interquartile range, CS corticosteroids, CS+TCZ corticosteroids + tocilizumab